Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vistagen Therapeutics, Inc. (EXCA) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vistagen Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1411685.
Total stock buying since 2017: $18,176,600.
Total stock sales since 2017: $147,150.
Total stock option exercises since 2017: $177,624.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 775,756 | $17,961,078 | 0 | $0 | 0 | $0 |
| 2022 | 900,000 | $154,199 | 60,000 | $53,400 | 118,750 | $118,750 |
| 2021 | 3,750 | $10,237 | 30,000 | $93,750 | 10,000 | $15,000 |
| 2020 | 30,000 | $20,700 | 0 | $0 | 0 | $0 |
| 2019 | 35,000 | $30,386 | 0 | $0 | 29,250 | $43,874 |
| 2017 | 100,000 | $0 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-08 | 775,756 | $17,961,078 | 0 | $0 | 0 | $0 |
| 2022-08 | 900,000 | $154,199 | 0 | $0 | 0 | $0 |
| 2022-07 | 0 | $0 | 60,000 | $53,400 | 0 | $0 |
| 2022-05 | 0 | $0 | 0 | $0 | 100,000 | $100,000 |
| 2022-01 | 0 | $0 | 0 | $0 | 18,750 | $18,750 |
| 2021-09 | 0 | $0 | 30,000 | $93,750 | 0 | $0 |
| 2021-08 | 3,750 | $10,237 | 0 | $0 | 0 | $0 |
| 2021-04 | 0 | $0 | 0 | $0 | 5,000 | $7,500 |
| 2021-03 | 0 | $0 | 0 | $0 | 5,000 | $7,500 |
| 2020-08 | 30,000 | $20,700 | 0 | $0 | 0 | $0 |
| 2019-11 | 15,000 | $5,100 | 0 | $0 | 0 | $0 |
| 2019-03 | 20,000 | $25,286 | 0 | $0 | 2,500 | $3,750 |
| 2019-01 | 0 | $0 | 0 | $0 | 26,750 | $40,124 |
| 2017-05 | 100,000 | $0 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-08-07 | Commodore Capital Lp | Buy | 775,756 | 23.15 | 17,961,078 |
| 2022-08-17 | Adler Reid G. (CHIEF LEGAL OFFICER) | Buy | 300,000 | .17 | 51,000 |
| 2022-08-17 | Singh Shawn (CHIEF EXECUTIVE OFFICER) | Buy | 600,000 | .17 | 103,199 |
| 2022-07-12 | Shah Nimish P (10% Owner) | Sale | 60,000 | .89 | 53,400 |
| 2022-05-12 | Singh Shawn (CHIEF EXECUTIVE OFFICER) | Option Ex | 100,000 | 1.00 | 100,000 |
| 2022-01-11 | Dotson Jerrold Duane (VP, CFO AND SECRETARY) | Option Ex | 18,750 | 1.00 | 18,750 |
| 2021-09-07 | Dotson Jerrold Duane (VP, CFO AND SECRETARY) | Sale | 30,000 | 3.12 | 93,750 |
| 2021-08-17 | Snodgrass H. Ralph (PRES./CHIEF SCIENTIFIC OFFICER) | Buy | 3,750 | 2.73 | 10,237 |
| 2021-04-23 | Singh Shawn (CHIEF EXECUTIVE OFFICER) | Option Ex | 5,000 | 1.50 | 7,500 |
| 2021-03-19 | Underdown Brian J. | Option Ex | 2,500 | 1.50 | 3,750 |
| 2021-03-19 | Saxe Jon S | Option Ex | 2,500 | 1.50 | 3,750 |
| 2020-08-21 | Saxe Jon S | Buy | 30,000 | .69 | 20,700 |
| 2019-11-20 | Snodgrass H. Ralph (PRES./CHIEF SCIENTIFIC OFFICER) | Buy | 15,000 | .34 | 5,100 |
| 2019-03-14 | Saxe Jon S | Buy | 7,920 | 1.27 | 10,090 |
| 2019-03-13 | Snodgrass H. Ralph (PRES./CHIEF SCIENTIFIC OFFICER) | Option Ex | 2,500 | 1.50 | 3,750 |
| 2019-03-13 | Saxe Jon S | Buy | 12,080 | 1.26 | 15,196 |
| 2019-01-29 | Saxe Jon S | Option Ex | 1,375 | 1.50 | 2,062 |
| 2019-01-14 | Singh Shawn (CHIEF EXECUTIVE OFFICER) | Option Ex | 25,375 | 1.50 | 38,062 |
| 2017-05-31 | Gin Jerry B | Buy | 100,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of EXCA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vistagen Therapeutics, Inc. (symbol EXCA, CIK number 1411685) see the Securities and Exchange Commission (SEC) website.